What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Surgery
Natasha B. Leighl mainly investigates Internal medicine, Lung cancer, Oncology, Surgery and Cancer.
Her study looks at the relationship between Internal medicine and topics such as Gastroenterology, which overlap with Mesothelioma.
Natasha B. Leighl has included themes like Survival rate, Carcinoma and Chemotherapy in her Lung cancer study.
Her research in Oncology intersects with topics in Docetaxel, KRAS, Epidermal growth factor receptor and Bioinformatics.
The study of Surgery is intertwined with the study of Placebo in a number of ways.
Her Cancer research incorporates themes from Anxiety, Prospective cohort study, Pathology and Combination chemotherapy.
Her most cited work include:
- Pembrolizumab for the treatment of non-small cell lung cancer (3324 citations)
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL (1224 citations)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (1122 citations)
What are the main themes of her work throughout her whole career to date?
Natasha B. Leighl mostly deals with Internal medicine, Oncology, Lung cancer, Cancer and Surgery.
In the field of Internal medicine, her study on Chemotherapy, non-small cell lung cancer, Clinical trial and Randomized controlled trial overlaps with subjects such as In patient.
Her Oncology study incorporates themes from Stage, Cisplatin, Docetaxel and Pathology.
Her research investigates the connection between Lung cancer and topics such as Cancer research that intersect with problems in Lung.
Cancer is closely attributed to Family medicine in her study.
Her studies in Surgery integrate themes in fields like Gastroenterology and Hazard ratio.
She most often published in these fields:
- Internal medicine (66.67%)
- Oncology (55.80%)
- Lung cancer (45.37%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (66.67%)
- Oncology (55.80%)
- Lung cancer (45.37%)
In recent papers she was focusing on the following fields of study:
Natasha B. Leighl focuses on Internal medicine, Oncology, Lung cancer, Cancer research and Cancer.
She performs multidisciplinary study in Internal medicine and In patient in her work.
Natasha B. Leighl combines subjects such as Hazard ratio, Phases of clinical research, Lung, Durvalumab and Stage with her study of Oncology.
Her work carried out in the field of Lung cancer brings together such families of science as Liquid biopsy, Quality of life and Epidermal growth factor receptor.
When carried out as part of a general Cancer research project, her work on Immune checkpoint is frequently linked to work in Focus group and Qualitative property, therefore connecting diverse disciplines of study.
The concepts of her Clinical trial study are interwoven with issues in Adverse effect and Randomized controlled trial.
Between 2018 and 2021, her most popular works were:
- Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study (238 citations)
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. (116 citations)
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update (64 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Lung cancer, Oncology, Cancer and Clinical trial are her primary areas of study.
Her Internal medicine and Adverse effect, Randomized controlled trial, Incidence, Nivolumab and Confidence interval investigations all form part of her Internal medicine research activities.
Natasha B. Leighl interconnects Combination therapy, Chemotherapy, Epidermal growth factor receptor and Cohort in the investigation of issues within Lung cancer.
Her Oncology research incorporates elements of Stage iv, Pembrolizumab, Immunotherapy and Hazard ratio.
Her work in the fields of Cancer, such as Immune checkpoint, intersects with other areas such as Focus group, Qualitative property and Pandemic.
Her Clinical trial research is multidisciplinary, relying on both Intensive care medicine, Placebo, Carcinoma, Erlotinib and Durvalumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
